Cargando…

Xu S, Wang S, Xing S, et al. KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2. Blood Adv. 2021;5(17):3241-3253.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006262/ https://www.ncbi.nlm.nih.gov/pubmed/35404434 http://dx.doi.org/10.1182/bloodadvances.2021006376

Ejemplares similares

Deen D, Butter F, Daniels DE, et al. Identification of the transcription factor MAZ as a regulator of erythropoiesis. Blood Adv. 2021;5(15):3002-3015.
Publicado: (2022)

Targeting TRIB3 and PML-RARα interaction against APL
por: Li, Ke, et al.
Publicado: (2017)

Singh A, Brandow AM, Panepinto JA. COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals. Blood Adv. 2021;5(7):1915-1921.
Publicado: (2022)

Duque-Afonso J, Ewald S, Ihorst G, et al. The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Adv. 2021;5(21):4327-4337.
Publicado: (2022)

KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RARα
por: Wang, Xinrui, et al.
Publicado: (2019)

Koh J, Jang I, Mun S, et al. Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Adv. 2021;5(20):3919-3930.
Publicado: (2022)

Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016.
Publicado: (2022)

Samra B, Khoury JD, Morita K, et al. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021;5(20):3913-3918.
Publicado: (2022)

Distribution of Different PML/RARα bcr Isoforms in Indian Acute Promyelocytic Leukemia (APL) Patients and Clinicohematological Correlation
por: Chatterjee, Tathagata, et al.
Publicado: (2014)

RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner
por: Xu, Lin, et al.
Publicado: (2017)

Regulation of NF-κB by PML and PML-RARα
por: Ahmed, Abrar, et al.
Publicado: (2017)

Wang et al (J Infect Dis 2016; 213:1380–7)
Publicado: (2016)

3241 Using infant exertion to tailor treadmill intervention
por: Westerdahl, Jacqueline E., et al.
Publicado: (2019)

Shouval R, Fein JA, Cho C, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6(5):1525-1535.
Publicado: (2022)

Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA
por: Gong, Xubo, et al.
Publicado: (2022)

Erratum for the Research Article: “Agriculture is a major source of NOx pollution in California” by M. Almaraz, E. Bai, C. Wang, J. Trousdell, S. Conley and I. Faloona, B. Z. Houlton
Publicado: (2018)

Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood. 2014;123(14):2204-2208.
Publicado: (2016)

Genome-wide functions of PML–RARα in acute promyelocytic leukaemia
por: Saeed, S, et al.
Publicado: (2011)

The limited contribution of DNA methylation to PML-RARα induced leukemia
por: Rohde, Christian, et al.
Publicado: (2013)

Targeting the Acute Promyelocytic Leukemia-Associated Fusion Proteins PML/RARα and PLZF/RARα with Interfering Peptides
por: Beez, Sabine, et al.
Publicado: (2012)

Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation
por: Wang, Qian Qian, et al.
Publicado: (2015)

Kundumani-Sridharan V, Niu J, Wang D, et al. 15(S)-hydroxyeicosatetraenoic acid–induced angiogenesis requires Src-mediated Egr-1–dependent rapid induction of FGF-2 expression. Blood. 2010;115(10):2105-2116.
Publicado: (2021)

PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL
por: di Masi, A, et al.
Publicado: (2016)

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia
por: Takenokuchi, Mariko, et al.
Publicado: (2012)

Palma-Barqueros V, Bury L, Kunishima S, et al. Expanding the genetic spectrum of TUBB1-related thrombocytopenia. Blood Adv. 2021;5(24):5453–5467.
Publicado: (2023)

RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells
por: Gianni, Maurizio, et al.
Publicado: (2016)

Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085-3092.
Publicado: (2022)

Kahn JM, Brazauskas R, Tecca HR, et al. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020;4(9):2084-2094.
Publicado: (2022)

Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.
Publicado: (2022)

PML‐RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia
por: Yang, Xianwen, et al.
Publicado: (2018)

Chromatin topology reorganization and transcription repression by PML-RARα in acute promyeloid leukemia
por: Wang, Ping, et al.
Publicado: (2020)

Eshel A, Sharon I, Nagler A, et al. Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis. Blood Adv. 2022;6(2):568-573.
Publicado: (2022)

Olin RL, Fretham C, Pasquini MC, et al. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4(12):2810-2820.
Publicado: (2022)

Vo P, Gooley, TA, Carpenter PA, et al. Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Adv. 2022;6(11):3220-3229.
Publicado: (2022)

Sensibilidad de detección para PML/RAR t(15,17) (q22,q21) de la leucemia promielocitica (PML)
por: Vásquez Pérez, María Isabel
Publicado: (2006)

Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.
Publicado: (2022)

Bornhauser B, Cario G, Rinaldi A, et al. The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Adv. 2020;4(17):4052-4064.
Publicado: (2022)

Miles J, Bailey SL, Obenaus AM, et al. Storage temperature determines platelet GPVI levels and function in mice and humans. Blood Adv. 2021;5(19):3839-3849.
Publicado: (2022)

Greenwood M, Trahair T, Sutton R, et al. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. Blood Adv. 2021;5(24):5574-5583.
Publicado: (2023)

Sulindac Sulfide Reverses Aberrant Self-Renewal of Progenitor Cells Induced by the AML-Associated Fusion Proteins PML/RARα and PLZF/RARα
por: Steinert, Gunnar, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9i3roqfki9h7thgfsg9e2cth2k